Lecigon (Entacapone, Levodopa, Carbidopa Monohydrate)

Lecigon, containing entacapone, levodopa and carbidopa, is used in the management of Parkinson's disease, a neurodegenerative disorder affecting dopaminergic pathways.

• Parkinson's disease (early to advanced stages): improves overall motor function and reduces the frequency of “off” periods when used with levodopa/carbidopa.
• Parkinson's disease with wearing‑off phenomenon: prolongs levodopa plasma half‑life, providing smoother symptom control throughout the day.
• Parkinson's disease patients experiencing motor fluctuations: helps maintain more consistent dopaminergic stimulation, supporting activities of daily living.

• Entacapone selectively inhibits catechol‑O‑methyltransferase (COMT) in peripheral tissues, preventing methylation of levodopa and thereby extending its plasma half‑life. Carbidopa competitively inhibits aromatic L‑amino‑acid decarboxylase outside the central nervous system, reducing peripheral conversion of levodopa to dopamine and increasing its availability for brain uptake. Levodopa crosses the blood‑brain barrier and is decarboxylated to dopamine within the CNS, restoring deficient dopaminergic neurotransmission in Parkinson’s disease.

Lecigon may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset often occurring after the first doses.
• Vomiting: occasional emesis related to gastrointestinal irritation.
• Dyskinesia: involuntary movements that may appear with increased dopaminergic activity.
• Orthostatic hypotension: dizziness or light‑headedness upon standing.
• Insomnia: difficulty falling or staying asleep.
• Dizziness: sensation of spinning or unsteadiness.

Serious or Rare Side Effects

• Severe liver injury: elevated transaminases or jaundice requiring medical attention.
• Neuroleptic malignant syndrome: high fever, muscle rigidity, and autonomic instability.
• Anaphylactic reaction: swelling, rash, and breathing difficulty.
• Hyperthermia: unexplained high body temperature.
• Rhabdomyolysis: muscle breakdown with dark urine and muscle pain.
• Suicidal thoughts: emergence of depressive symptoms or suicidal ideation.

When prescribing Lecigon, clinicians should consider several safety measures.

• Dose adjustment: titrate according to clinical response and tolerability.
• Renal impairment: monitor function and consider dose modification.
• Hepatic impairment: use with caution; monitor liver enzymes.
• Cardiovascular disease: watch for orthostatic hypotension.
• Concomitant MAO‑B inhibitors: avoid due to risk of hypertensive crisis.
• Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Lecigon interacts with several drug classes; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid)

• Non‑selective MAO inhibitors: risk of hypertensive crisis.
• Anticholinergic agents: may mask Parkinsonian symptoms.
• Antihypertensive drugs: additive orthostatic hypotension.
• SSRIs/SNRIs combined with MAO‑B inhibitors: increased serotonin syndrome risk.
• Iron supplements: reduce levodopa absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• Antipsychotics: may reduce levodopa efficacy.
• Diuretics: may exacerbate electrolyte imbalance.